NewTimeSpace News, May 11,SIA Engineering Company Limited disclosed in an announcement that its wholly-owned subsidiary, NexGen Network (2) Holding Pte. Ltd. (NGN2), has been placed under voluntary liquidation with liquidators appointed.
NewTimeSpace News: Trendlines disclosed in an announcement dated May 11 that the company’s Audit Committee and Board of Directors have approved an investment by an LH affiliate into portfolio companies Ceretrieve Ltd. and Vensica Medical Ltd.
NewTimeSpace News, May 11,OUE Limited disclosed in an announcement that its wholly-owned subsidiary, OUE Treasury Pte. Ltd., proposes to issue S$150 million 3.25% green notes due 2033.
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (01276.HK) announced that it has signed a global strategic collaboration and license agreement with Bristol Myers Squibb (BMS) on May 12, 2026, to jointly advance 13 early-stage projects covering oncology, hematology, and immunology.BMS will pay Hengrui an upfront payment and annual payments of up to US$950 million. The potential total transaction value is approximately US$15.2 billion, including milestone payments.
NewTimeSpace News: Suzhou Riborn Biotech Co., Ltd. (06938.HK) announced that its core product vortosiran (RBD4059) has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE).Vortosiran is the world’s most advanced small nucleic acid drug targeting FXI. It has previously completed a Phase 2a clinical trial in Europe for coronary artery disease.
NewTimeSpace News, By the close of trading on May 11, 2026, EVEREST GOLD(01815.HK) saw a loss of 8.49% in its share price, closing at HKD 0.97. During the session, it reached an intraday high of HKD 1.05 and touched an intraday low of HKD 0.96.
NewTimeSpace News, By the close of trading on May 11, 2026, LDROBOT(01236.HK) saw a gain of 127.62% in its share price, closing at HKD 60. During the session, it reached an intraday high of HKD 66 and touched an intraday low of HKD 50.3.
NewTimeSpace News: Cansino Biologics Inc. (06185.HK) announced that the New Drug Application (NDA) for its Adsorbed Acellular Pertussis (5-Component) Diphtheria and Tetanus Combined Vaccine (for people aged 6 and above) (Td5cp for adolescents and adults) has been granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.Indicated for people aged 6 and above, it serves as a booster vaccine for adolescents and adults. No similar product has been approved in China to date.
NewTimeSpace News: CGN Power Co., Ltd. (01816.HK) announced that Huizhou Unit 4, developed by its subsidiary CGN Huizhou Second Nuclear Power Co., Ltd., carried out the First Concrete Pouring (FCD) of the nuclear reactor main building on May 10, 2026. This marks the full-scale construction commencement of the unit, entering the civil engineering phase. Huizhou Unit 4 has an installed capacity of 1,209MW.
NewTimeSpace News, May 11,QBE Insurance disclosed in an announcement that, pursuant to Condition 10.3 of the terms and conditions of the subordinated notes, the company will redeem all of its outstanding 5.875% fixed rate subordinated notes on June 17, 2026, with an aggregate principal amount of approximately US$524 million.
NewTimeSpace News, May 11,iX Biopharma disclosed in an announcement that it will undertake an internal restructuring of its consumer business, consolidating relevant assets under a newly incorporated holding company, Ligo Pharma Pte Ltd, as a dedicated platform to pursue the US consumer health market.
NewTimeSpace News, May 11,Geo Energy Resources Limited announced that it has entered into a term sheet with Resource Invest AG, under which ResInvest intends to invest in the Group‘s MBJ integrated infrastructure business, valued at US$1.5 billion.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has entered into an exclusive strategic cooperation with GlaxoSmithKline (GSK). Chia Tai Tianqing will be responsible for the import, distribution, hospital access and promotion of bepirovirsen in Chinese Mainland.Bepirovirsen is a first-in-class antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB) in adults. It has been included in both the Breakthrough Therapy Designation and Priority Review process. There are approximately 75 million hepatitis B virus-infected individuals in China.
NewTimeSpace News: YUM CHINA(09987.HK) will spend USD 11.13 million to repurchase 235.12 thousand shares on May 8, 2026.
NewTimeSpace News: CONANT OPTICAL(02276.HK) will spend HKD 21.03 million to repurchase 450 thousand shares on May 8, 2026.
NewTimeSpace News: STANCHART(02888.HK) will spend GBP 5.87 million to repurchase 308 thousand shares on May 7, 2026.
